Ozempic FDA Approval History
FDA Approved: Yes (First approved December 5, 2017)
Brand name: Ozempic
Generic name: semaglutide
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Diabetes, Type 2, Cardiovascular Risk Reduction
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog indicated:
- as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
Development Timeline for Ozempic
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.